Public health benefits of partner notification for sexually transmitted infections and HIV
This report provides a better understanding of current policies and practice related to partner notification in Europe and evaluates its public health benefits, and particularly its role in STI and HIV prevention. It also reveals the wide variety of partner notification practices in Europe which are determined by diverse legal and policy frameworks, and influenced by cultural and social factors.
To explore and evaluate current partner notification policies and practices across Europe, ECDC gathered information about existing national legal and policy frameworks. In 11 of the 24 countries that responded to the ECDC questionnaires, laws or regulations exist that make partner notification compulsory for the health care provider, the patient or both. These laws most often apply to HIV, syphilis, gonorrhoea, chlamydia, hepatitis B, and hepatitis C. While some countries have wide-ranging legal obligations to enforce partner notification, others have laws that are not enforced, and some countries have no such obligations or laws.
In general, “partner notification” describes the process when the sexual partner(s) of a patient who was diagnosed with a sexually transmitted infection (STI) are identified and informed of their exposure. During this process, the sexual partner(s) are normally invited for testing, counselling and, where necessary, treatment.
There are different approaches to partner notification which can be broadly defined as:
- patient referral, i.e. the tested patient takes the responsibility for informing their sexual partner(s) of a possible STI exposure and for referring them to services,
- provider referral where the test provider informs the sexual partner(s), and
- contract or conditional referral, where the provider informs the sexual partner(s) in case the patient fails to do so within an agreed period of time.
Patient referral preferred approach
The report shows that patient referral is the preferred approach to partner notification for all STI in most EU/EEA countries. Provider referral was used in some countries, most often for syphilis, gonorrhoea, chlamydia and HIV.
The majority of health care providers see the value of partner notification. There is little support for mandatory partner notification and concern about use of provider referral, in particular for HIV partner notification, because of patient confidentiality issues.
Partner notification has clear clinical benefits: it aims to prevent re-infection of the index patient and treat their sexual partner(s). And at the same time it also has public health benefits as partner notification aims to control the spread of STI and reduce STI-related sickness and deaths.
Information for this report was obtained through three online questionnaires, in-depth interviews with health professionals and policy-makers and literature reviews.
The use of evidence in decision making during public health emergencies
26 Jul 2019 - This report is based upon a workshop (expert consultation) on 5–6 December 2018. The workshop sought to identify and address the links between scientific evidence and decision-making in public health emergencies, and to address the key challenges faced by public health experts when advising decision makers.
Syphilis and congenital syphilis in Europe - A review of epidemiological trends (2007–2018) and options for response
12 Jul 2019 - Since 2010, syphilis notification rates in the EU/EAA have been on the increase, but in recent years this trend seems to accelerate, predominantly among men having sex with men. Similar trends have been observed in high-income countries outside the EU/EAA. While the overall trend remained relatively stable, outbreaks or clusters of syphilis cases have also been reported among heterosexual populations in the EU/EEA. In several high-income countries (e.g. USA, Japan), increases in congenital syphilis occurred in connection with increases in syphilis notifications among women.
Collection and analysis of whole genome sequencing data from food-borne pathogens and other relevant microorganisms isolated from human, animal, food, feed and food/feed environmental samples in the joint ECDC–EFSA molecular typing database
29 May 2019 - This report identifies and compares potential platforms/solutions for the set-up and running of a joint ECDC–EFSA database to collect and analyse whole genome sequencing (WGS) data for Listeria monocytogenes, Salmonella and Escherichia coli. In particular, WGS introduces the need for specific components for storage and analysis of these data.